Colleen Kane

4.3k total citations · 2 hit papers
46 papers, 3.4k citations indexed

About

Colleen Kane is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Colleen Kane has authored 46 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Hematology and 12 papers in Oncology. Recurrent topics in Colleen Kane's work include Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Parasites and Host Interactions (7 papers). Colleen Kane is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Parasites and Host Interactions (7 papers). Colleen Kane collaborates with scholars based in United States, Spain and Netherlands. Colleen Kane's co-authors include Robin J. Flynn, Daniel R. Neill, Christine M. Bucks, Andrew N. J. McKenzie, See Heng Wong, Helen E. Jolin, Maria Daly, Padraic G. Fallon, Richard Pannell and Edward J. Pearce and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Colleen Kane

40 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

2010 1.6k citations Daniel R. Neill, See Heng Wong et al. Nature profile →
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers

Countries citing papers authored by Colleen Kane

Since Specialization

Citations

This map shows the geographic impact of Colleen Kane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colleen Kane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colleen Kane more than expected).

Fields of papers citing papers by Colleen Kane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colleen Kane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colleen Kane. The network helps show where Colleen Kane may publish in the future.

Co-authorship network of co-authors of Colleen Kane

This figure shows the co-authorship network connecting the top 25 collaborators of Colleen Kane. A scholar is included among the top collaborators of Colleen Kane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colleen Kane. Colleen Kane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, (unknown), Paula Rodríguez‐Otero, María-Victoria Mateos, (unknown), Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari	5
2	P-098 Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, (unknown), Leo Rasche, Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari	0
3	P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Eric M. Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Xinke Zhang, Luciano da Fontoura Costa	1
4	MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, (unknown), Paula Rodríguez‐Otero, María‐Victoria Mateos, (unknown), Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari	9
5	Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model 2024 ·Targeted Oncology ·(unknown), (unknown), Brandi Hilder, Tara Masterson, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Loeckie De Zwart, Suzette Girgis, Xuewen Ma, Danièle Ouellet	1
6	GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review breakdown → 2024 ·Blood Cancer Journal ·Paula Rodríguez‐Otero, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar J. Bahlis, Ajai Chari	51
7	Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414) 2020 ·JTO Clinical and Research Reports ·Rathi N. Pillai, Suresh S. Ramalingam, Meena Thayu, Patricia Lorenzini, Diana Alvarez Arias, Christopher Moy, Natalie A. Hutnick, Roland E. Knoblauch, Huaibao Feng, Colleen Kane, Leora Horn, Martin Reck, Santiago Ponce	11
8	Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics 2015 ·Protein Engineering Design and Selection ·Steven Jacobs, Alan C. Gibbs, (unknown), Yi Fang, Diane Maguire, Colleen Kane, Karyn T. O’Neil	54
9	Inhalation Delivery of Protein Therapeutics 2013 ·Inflammation & Allergy - Drug Targets ·Colleen Kane, Karyn T. O’Neil, (unknown), Kristen Picha	16
10	Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity breakdown → 2010 ·Nature ·Daniel R. Neill, See Heng Wong, (unknown), Robin J. Flynn, Maria Daly, (unknown), Christine M. Bucks, Colleen Kane, Padraic G. Fallon, Richard Pannell, Helen E. Jolin, Andrew N. J. McKenzie	1632
11	Review series on helminths, immune modulation and the hygiene hypothesis: Mechanisms underlying helminth modulation of dendritic cell function 2008 ·Immunology ·Lucas P. Carvalho, Jie Sun, Colleen Kane, Fraser A. Marshall, Connie M. Krawczyk, Edward J. Pearce	71
12	Cryoplane fluorescence microscopy 2006 ·Jonathan Nissanov, (unknown), (unknown), (unknown), Colleen Kane, Kenneth W. Gross, Douglas G. Baird	4
13	Dendritic Cell-Intrinsic Expression of NF-κB1 Is Required to Promote Optimal Th2 Cell Differentiation 2005 ·The Journal of Immunology ·David Artis, Colleen Kane, (unknown), Colby Zaph, Sagi Shapira, Karen L. Joyce, Andrew S. MacDonald, Christopher A. Hunter, Phillip Scott, Edward J. Pearce	47
14	Regulation of Dendritic Cell Function by Pathogen-Derived Molecules Plays a Key Role in Dictating the Outcome of the Adaptive Immune Response 2005 ·PubMed ·Edward J. Pearce, Colleen Kane, Jie Sun	51
15	Cutting Edge: Dendritic Cells Copulsed with Microbial and Helminth Antigens Undergo Modified Maturation, Segregate the Antigens to Distinct Intracellular Compartments, and Concurrently Induce Microbe-Specific Th1 and Helminth-Specific Th2 Responses 2004 ·The Journal of Immunology ·Laura Cervi, Andrew S. MacDonald, Colleen Kane, Florence Dzierszinski, Edward J. Pearce	146
16	Helminth Antigens Modulate TLR-Initiated Dendritic Cell Activation 2004 ·The Journal of Immunology ·Colleen Kane, Laura Cervi, Jie Sun, Amy S. McKee, (unknown), Sagi Shapira, Christopher A. Hunter, Edward J. Pearce	192
17	Th2 response polarization during infection with the helminth parasite Schistosoma mansoni 2004 ·Immunological Reviews ·Edward J. Pearce, Colleen Kane, Jie Sun, Justin J. Taylor, Amy S. McKee, Laura Cervi	157
18	Role of angiotensin II in altered baroreflex function of conscious rabbits during late pregnancy 2001 ·American Journal of Obstetrics and Gynecology ·Virginia L. Brooks, Lisa S. Welch, Colleen Kane	14
19	Angiotensin II receptor blockade with losartan does not increase baroreflex gain in conscious, pregnant rabbits 1998 ·The FASEB Journal ·Lisa S. Welch, Colleen Kane, Virginia L. Brooks	1
20	Expression of the Mouse Ren-1 Gene in the Coagulating Gland: Localization and Regulation1 1993 ·Biology of Reproduction ·John R. Fabian, Colleen Kane, Kenneth J. Abel, Kenneth W. Gross	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact